Entering text into the input field will update the search result below

Acura, Abuse Deterrent Pharmaceuticals amend license deal for pain drug LIMITx LTX-03

Mar. 01, 2022 6:55 AM ETAcura Pharmaceuticals, Inc. (ACUR)By: Ravikash, SA News Editor

Prescription Medication Medicine Pill Tablets

EHStock/iStock via Getty Images

  • Acura Pharmaceuticals (OTCQB:ACUR) amended a license, development and commercialization agreement for its product candidate LIMITx LTX-03 with Abuse Deterrent Pharmaceuticals to extend the new drug application (NDA) acceptance date by FDA to Dec. 31.
  • The company expects to complete clinical

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.